Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04398758
Other study ID # MOPAD
Secondary ID 2018-004762-33
Status Recruiting
Phase Phase 3
First received
Last updated
Start date July 22, 2020
Est. completion date June 2024

Study information

Verified date June 2022
Source Infectopharm Arzneimittel GmbH
Contact Tanja Wehran, Dr.
Email studien@infectopharm.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, it will be investigated if symptoms of atopic dermatitis of children with high familial risk will be delayed beyond the 6th or even 12th month of life by applying the SanaCutan Basiscreme.


Description:

Enrolled healthy newborns with high risk for atopic dermatitis will be 1:1 randomised into treatment and control group. The treatment group receives the SanaCutan Basiscreme for twice daily skin application until the age of 6 months (main phase; half of them until the age of 12 months (main + follow-up phase)), whereas the control group should avoid skin care products. Guardians of both groups are requested to document all applied skin care products in a diary. In regular visits at the study sites, a blinded physician investigates the skin of the children. In case of an atopic dermatitis (= atopic dermatitis has to be diagnosed in at least two visits with an interval of at least four weeks), the severity will be examined (SCORAD) and the treatment with SanaCutan Basiscreme will be terminated. All children will be followed up until the age of 6 months (end of main phase). This is the time when a blood test will be conducted to determine sensitization against food and inhalant allergens and total IgE. If children do not develop an atopic dermatitis in the main phase, the study continues until they receive the diagnosis (up to a maximum of 12 months, end of follow-up phase).


Recruitment information / eligibility

Status Recruiting
Enrollment 360
Est. completion date June 2024
Est. primary completion date December 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 21 Days
Eligibility Inclusion Criteria: - Healthy newborns (male or female) - Age < 3 weeks (= 21st day of life) - High familial risk of atopic dermatitis in the form of at least one first-degree relative (parent or sibling) with a medically diagnosed atopic dermatitis in the medical history - Written consent of all guardians Exclusion Criteria: - Acute or chronic diseases - Acute fever (> 38.5 °C) - Severe congenital malformations - Hydrops fetalis - Immunodeficiency (any kind) - Severe genetic skin diseases or skin conditions that make the use of skin creams unsuitable - Corticoid or calcineurin inhibitor use or Ciclosporin intake - Preterm birth (< 37 weeks) - Known hypersensitivity to one of the ingredients of the SanaCutan Basiscreme - Restricted legal capacity of the guardians - Inability of the guardians to understand the study instructions - Obvious unreliability or lack of cooperation of the guardians - Known alcohol, medicine or drug dependency of the guardians - Dependence of the child or guardians on the sponsor or the investigator - Previous participation in another clinical trial (since birth) - Previous participation in this study

Study Design


Intervention

Drug:
SanaCutan Basiscreme
In this study, the SanaCutan Basiscreme will be used as a cream for twice daily application on the whole body (eyes and mucous membranes have to be omitted) for a duration of 6 months (main phase) or 12 months (main + follow-up phase) or less (if the child develops atopic dermatitis).

Locations

Country Name City State
Germany Gemeinschaftspraxis Bauer, Gilb, von Bentzel Augsburg
Germany Universitätsklinikum Augsburg Augsburg
Germany Charité Universitätsmedizin Berlin
Germany Evangelisches Klinikum Bethel Bielefeld
Germany Katholisches Klinikum Bochum gGmbH Bochum
Germany St. Marien-Hospital Bonn
Germany Evangelisches Krankenhaus Düsseldorf Düsseldorf
Germany Barmherzige Brüder Klinik St. Hedwig Regensburg
Germany Gemeinschaftspraxis für Kinder- und Jugendmedizin Tuttlingen
Germany Marien Hospital Wesel Wesel

Sponsors (2)

Lead Sponsor Collaborator
Infectopharm Arzneimittel GmbH Gesellschaft für Therapieforschung mbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative incidence of children with atopic dermatitis at 6 months of age A confirmed atopic dermatitis is present if an atopic dermatitis is diagnosed in at least 2 examinations at intervals of at least 4 weeks (preliminary diagnosis + proof of chronification).
The primary objective is achieved when the cumulative incidence of children with atopic dermatitis in the treatment group at 6 months of age is significantly lower than in the control group without predetermined treatment (p < 0.05).
0-6 months of age
Secondary Cumulative incidence of children with atopic dermatitis at the age of 12 and 16 weeks and 9, 12 and 6-12 months 0-12 months of age
Secondary Cumulative incidence of children with preliminary diagnosis of atopic dermatitis (regardless of whether chronification is confirmed) at 12 and 16 weeks and 6, 9 and 12 months 0-12 months of age
Secondary Time to onset of atopic dermatitis at the age of 0-6, 6-12 and 0-12 months 0-12 months of age
Secondary Cumulative incidence and frequency of children with xerosis at the age of 6 and 12 months 0-12 months of age
Secondary Cumulative incidence and frequency of children with signs of itching at 6 and 12 months of age 0-12 months of age
Secondary Cumulative incidence and frequency of children with other types of eczema at 6 and 12 months of age 0-12 months of age
Secondary Severity of atopic dermatitis at the time of detection of (confirmed) atopic dermatitis up to the age of 12 and 16 weeks and 6, 9 and 12 months Method: SCORAD (SCORing Atopic Dermatitis; 0-104 points; higher score indicates a more severe atopic dermatitis) 0-12 months of age
Secondary Frequency of sensitization to food allergens (according to Fx5 test + hazelnut) and to inhalation allergens (according to Sx1 test) and total IgE at the age of 6, 9 and 12 months Positive/negative of Fx5 test and Sx1 test and - in case of a positive result - on a single allergen basis (with specific IgE value). The measures of sensitization and total IgE are performed for all children at the age of 6 months and again for children in the follow-up phase, if they are diagnosed with atopic dermatitis in this period of time. 0-12 months of age
Secondary Adverse events: overall frequency, type, severity, causality, with frequencies, separate presentation of local reactions up to the age of 6 and 12 months 0-12 months of age
Secondary Drop-outs (with reasons) up to the age of 6 and 12 months 0-12 months of age
Secondary Compliance regarding the use of the investigational medicinal product in the treatment group up to the age of 6, 12 and 6-12 months 0-12 months of age
Secondary Compliance regarding the use of other skin care products (not investigational medicinal product) in both groups up to the age of 6, 12 and 6-12 months 0-12 months of age
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2